24
January
2024
|
08:29 AM
Europe/Amsterdam

Application for regulatory approval of Aflibercept 8 mg accepted in China

Not intended for U.S. and UK Media

Summary

Study data are now under review by the regulatory body in China / Submission refers to treatment of wet age-related macular degeneration based on the phase III study PULSAR, that demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with comparable visual acuity and faster fluid control to the comparator Eylea (aflibercept 2 mg) with a fixed 8-week treatment interval through to week 48 / Safety profile of aflibercept 8 mg was similar to Eylea (aflibercept 2 mg) / Extended treatment intervals address an important patient need

Berlin, January 24, 2024 – Bayer today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) accepted the submission of an application for regulatory approval of aflibercept 8 mg for the treatment of neovascular (wet) age-related macular degeneration (nAMD). Study data are now under review by the regulatory body in China. The application is based on positive results from the phase III PULSAR trial in nAMD, in which aflibercept 8 mg met its primary endpoint of non-inferiority in best corrected visual acuity (BCVA) changes compared to Eylea (aflibercept 2 mg) with a fixed 8-week treatment interval at week 48. Aflibercept 8 mg demonstrated unprecedented durability with the vast majority of patients maintaining 12- or 16-week dosing intervals.

“Retinal disease is a significant health issue in China. For patients living with neovascular age-related macular degeneration, losing visual function substantially impacts their lives. It can result in loss of independence and an inability to conduct simple tasks such as reading, writing, and getting dressed. Although effective treatments are available, long-term treatment adherence can be difficult for these patients. Extended treatment intervals can address this important patient need by reducing the number of injections and alleviating the burden on patients,” said Dr. Christian Rommel, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of Research and Development.

At week 48 in the PULSAR clinical trial, aflibercept 8 mg, dosed with extended treatment intervals (every 12 or every 16 weeks) demonstrated comparable visual acuity to the standard of care Eylea (aflibercept 2 mg) with a fixed 8-week treatment interval, following three initial monthly doses. Aflibercept 8 mg showed unprecedented durability with 77% of nAMD patients randomized to the 16-week dosing arm achieving and maintaining 16-week treatment intervals with an average of only 5 injections through week 48. Of those nAMD patients randomized to the aflibercept 8 mg 12-week dosing arm, 79% maintained their interval with an average of 6 injections through week 48. In addition, aflibercept 8 mg showed faster fluid control to the comparator Eylea (aflibercept 2 mg) through to week 48.

The safety of aflibercept 8 mg was similar to the well-established safety profile of Eylea (aflibercept 2 mg) and consistent with previous clinical trials. The rates of intraocular inflammation and intraocular pressure increase for aflibercept 8 mg were low and similar to Eylea (aflibercept 2 mg). There were no cases of endophthalmitis, retinal vasculitis and no new safety signals through to week 48.

Eylea HD (aflibercept 8 mg) has been approved for use by the FDA in August 2023. To date, Eylea™ 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) has been approved in the EU, Japan and other markets for the treatment of nAMD and DME. Bayer has submitted regulatory applications for aflibercept 8 mg in additional markets.

Eylea 8 mg (aflibercept 8 mg; in the United States: Eylea HD) is being jointly developed by Bayer and Regeneron. Regeneron maintains exclusive rights to Eylea 2 mg (aflibercept 2 mg) and Eylea HD in the United States. Bayer has licensed the exclusive marketing rights outside the United States, where the companies share equally the profits from sales of Eylea 2 mg and Eylea 8 mg following any regulatory approvals.

About PULSAR
PULSAR is a double-masked, active-controlled pivotal phase III trial, conducted in multiple centers globally. PULSAR evaluated the efficacy and safety of aflibercept 8 mg in nAMD with 12- and 16-week dosing regimens versus Eylea (aflibercept 2 mg) dosed every 8 weeks, following initial monthly doses, with the primary endpoint of non-inferiority in terms of best corrected visual acuity (BCVA) at week 48. Patients were randomized at baseline and assigned to the three different arms. In PULSAR, 1,009 patients were treated. All patients in the aflibercept 8 mg arms were continuously evaluated under stringent, clinically relevant, patient focused dose regimen modification (DRM) criteria starting from week 16 throughout the study. Patients on aflibercept 8 mg arms were assessed at multiple time points for DRM criteria and may have had their dosing interval shortened to 8 or 12 weeks to secure appropriate disease control through week 48.

About nAMD
Neovascular (wet) age-related macular degeneration (nAMD) is an eye disease that progresses rapidly and if left untreated can lead to vision loss in a few months. nAMD is one of the leading causes of irreversible blindness and vision impairment around the world. nAMD may affect people as they age. It occurs when abnormal blood vessels grow and leak fluid under the macula, the part of the eye responsible for sharp central vision and seeing fine detail. This fluid can damage and scar the macula, which can cause vision loss. 196 million people worldwide are living with AMD – it is anticipated that this figure will increase to 288 million by 2040.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com
Follow us on Facebook: http://www.facebook.com/bayer

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Downloads

Sign up for our Newsletter

We will keep you informed about the latest news.